Savolitinib

Savolitinib

Clinical data
Other names	Volitinib
Identifiers
IUPAC name 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
CAS Number	1313725-88-0
ChemSpider	34501055
UNII	2A2DA6857R
KEGG	D11139
ECHA InfoCard	100.238.920
Chemical and physical data
Formula	C17H15N9
Molar mass	345.370 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
InChI InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1 Key:XYDNMOZJKOGZLS-NSHDSACASA-N

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.

External links

• "Savolitinib". Drug Information Portal. U.S. National Library of Medicine.